Navigation Links
Notre Dame researcher's paper examines the biology of tumor-derived microvesicles
Date:6/21/2012

A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients.

The World Health Organization (WHO) estimates that the incidence of cancer will reach approximately 9 million deaths in 2015. The rising prevalence of the disease is a major factor that drives the growth of the oncology biomarkers market. Biomarkers can be defined as any biological, chemical or physical parameter that can be utilized as an indicator of physiological or disease status. Thus, biomarkers are useful in cancer screening and detection, drug design and also to boost the effectiveness of cancer care by allowing physicians to tailor therapies for individual patientsan approach known as personalized medicine.

The new paper discusses the potential of microvesicles to present a combination of disease and tissue-specific markers that would constitute a unique, specific and identifiable biosignature for individual cancers.

"As such, it would make their sampling over time a preferred method to monitor changes to the tumor in response to treatment, especially for tissues such as the ovary or pancreas, where repeated biopsies of these organs is impractical," D'Souza-Schorey said.

Profiling of microvesicles could form the basis of personalized, targeted cancer therapies, especially as more reliable and rapid profiling technologies become available.

"For example, certain markers like HER2/neu, in addition to being elevated in breast cancer, is also increased in a relatively smaller subset of other cancers such as ovarian cancer," D'Souza-Schorey said. "This latter group of patients would benefit from existing treatment strategies that target the HER2 receptor."

The approach could be advantageous over currently used approaches of profiling whole tissue or un-fractionated body fluid particularly if circulating microvesicles indeed concentrate molecular changes that occur in the tumor, as it would increase the sensitivity of detecting critical markers of cancer progression.

"One complicating factor, though, is the presence of shed vesicles from other non-tumor cell types also in direct contact with these body fluids," D'Souza-Schorey said. "Thus, equally significant is the development of strategies to selectively capture tumor-specific markers that separate from other shed vesicle populations."

In collaboration with local oncologists, the D'Souza-Schorey laboratory is investigating the potential of microvesicles as a cancer diagnostic platform, a project under the umbrella of Notre Dame's Advanced Diagnostics and Therapeutics Initiative. The lab's research on the biology of microvesicles and their roles in tumor progression is supported by the National Cancer Institute and the Indiana Clinical and Translational Sciences Institute.

"Despite considerable strides, effort and investment in cancer biomarker research in the past decade, there are still more desirable outcomes, most especially enhanced sensitivity to enable early detection ," D'Souza-Schorey said. "An effective biomarker platform that will overcome these challenges would be paradigm shifting in cancer care."

The paper, which appears in the June 15 issue of the journal Genes and Development, was coauthored by Notre Dame graduate student James Clancy.


'/>"/>

Contact: Crislyn-D'Souza-Schorey
cdsouzas@nd.edu
574-631-3735
University of Notre Dame
Source:Eurekalert

Related medicine news :

1. Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment
2. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
3. Controversial vaccine trial should never have been run in India, researchers say
4. Researchers create the first GPS for the blind
5. Researchers find gold nanoparticles capable of unzipping DNA
6. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
7. Researchers reveal crucial immune fighter role of the STING protein
8. MDS researchers join forces to advance patient treatments and outcomes
9. Stanford researchers discover the African cichlids noisy courtship ritual
10. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
11. UCI researchers create mosquitoes incapable of transmitting malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... 19, 2017 , ... The American College of Lifestyle ... recently formed Corporate Roundtable, a group of individuals and organizations whose collective vision ... Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and programs ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets ... (published by Xlibris on July of 2014). This book details the recent advances and ... approaches that benefit people who have lost all of their natural teeth . ...
(Date:9/19/2017)... Va (PRWEB) , ... September 19, 2017 , ... The ... the use of health IT to create efficiencies in healthcare information exchange and a ... the release of their latest industry white paper, entitled Barriers to Adoption of ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology: